financetom
Business
financetom
/
Business
/
Alamos Gold's Price Target Raised to US$18 from US$16 by RBC Capital Markets on Expected Closing of Argonaut Deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Alamos Gold's Price Target Raised to US$18 from US$16 by RBC Capital Markets on Expected Closing of Argonaut Deal
Apr 23, 2024 8:21 AM

10:45 AM EDT, 04/23/2024 (MT Newswires) -- Alamos Gold ( AGI ) maintained its "Outperform" rating and saw its price target raised to US$18 from US$16 at RBC Capital Markets on Tuesday, after assuming the successful closing of AGI's planned acquisition of Argonaut Gold ( ARNGF ) .

"We continue to see the transaction as strongly accretive, strategically sound (with little risk of an interloper emerging), and adding to the forecasted organic growth across the portfolio over the next four years," the bank said.

RBC updated its valuation and estimates for Alamos after "baking" Argonaut's Magino operation into Alamo's Island Gold model (near 50% of total NAV) leading to near 15% higher NAVPS/sFCF.

According to RBC, the integration would boost Alamos' immediate production in the third quarter as its deal for Argonaut is expected to close in July, RBC said.

RBC said management expects Magino and Island Gold to be treated as one mining complex, sharing the existing Magino mill and tailings storage facility while producing over 400,000 ounce per year of gold at AISC under $1,000/oz at full production in 2027 and beyond.

RBC expects to see "strong accretion" both near and long term and "more levers to pull on growth".

"We see [Alamos'] stable production, strong track record of execution, organic growth, and exposure to Canada as justifying the current premium to mid-cap peers," RBC said.

Alamos' share price was up 1% to $20.44 per share at last look.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Unilever picks Amsterdam over London for primary ice cream listing
Unilever picks Amsterdam over London for primary ice cream listing
Feb 13, 2025
* Demerges ice cream business; Amsterdam is primary listing * Move seen as blow to UK's Reeves, despite listing reforms * Shares fall 6.9% in London after results, announcement (Adds UK business minister comment in paragraph 8; CEO comment in paragraphs 13 and 18) By Yadarisa Shabong and Richa Naidu Feb 13 (Reuters) - Ben & Jerry's ( UL )...
Zoetis Q4 Adjusted Earnings, Revenue Increase; Provides 2025 Guidance
Zoetis Q4 Adjusted Earnings, Revenue Increase; Provides 2025 Guidance
Feb 13, 2025
07:27 AM EST, 02/13/2025 (MT Newswires) -- Zoetis ( ZTS ) reported Q4 adjusted earnings Thursday of $1.40 per diluted share, up from $1.24 a year earlier. Analysts polled by FactSet expected $1.36. Revenue for the quarter ended Dec. 31 was $2.32 billion, compared with $2.21 billion a year earlier. Analysts surveyed by FactSet expected $2.30 billion. The company said...
Thomson Reuters Says to Transfer U.S. Stock Exchange Listing to Nasdaq
Thomson Reuters Says to Transfer U.S. Stock Exchange Listing to Nasdaq
Feb 13, 2025
07:29 AM EST, 02/13/2025 (MT Newswires) -- Thomson Reuters ( TRI ) , a global content and technology company, on Thursday announced that it will voluntarily transfer its U.S. stock exchange listing to the Nasdaq Global Select Market from the New York Stock Exchange. The company expects that its common shares will cease trading on the NYSE at market close...
J&J, Sanofi stop E.coli vaccine trial due to low effectiveness
J&J, Sanofi stop E.coli vaccine trial due to low effectiveness
Feb 13, 2025
Feb 13 (Reuters) - Johnson & Johnson ( JNJ ) and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by the E.coli bacteria due to a lack of sufficient efficacy, the companies said on Thursday. No safety issues related to the experimental vaccine were identified after an independent review, J&J said and added...
Copyright 2023-2026 - www.financetom.com All Rights Reserved